Promising new drug shows hope for rare, severe skin disease

NCT ID NCT03619902

Completed Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 19 times

Summary

This study tested a new drug called imsidolimab in 8 adults with active generalized pustular psoriasis (GPP), a rare and serious skin condition that causes painful pustules. The goal was to see if the drug could improve skin symptoms and was safe. Results showed that most participants had meaningful improvement in their skin within weeks, suggesting imsidolimab may help control this disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Site 100

Ann Arbor, Michigan, 48109, United States
Site 101

Indianapolis, Indiana, 46250, United States
Site 102

Encino, California, 91436, United States
Site 104

Miami, Florida, 33316, United States
Site 105

Largo, Florida, 33771, United States
Site 201

London, United Kingdom
Site 202

Salford, United Kingdom
Site 203

Newcastle upon Tyne, United Kingdom
Site 301

Rzeszów, 35-055, Poland
Site 302

Lodz, Poland
Site 303

Lodz, 90-436, Poland
Site 304

Olsztyn, 10-229, Poland
Site 501

Seoul, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

GENERALIZED PUSTULAR PSORIASIS